FindTrial
Sign In

Either Panchvalkaladi Taila or Dashamoola Taila mixed with cotton gauzepiece and keep in Vagina along with orally Punarnavadi Guggulu will be used for Pelvic inflammation

Efficacy Of Punarnavadi Guggulu Orally,Panchavalkaladi Taila Yonipichu And Dashamoola Taila Yonipichuin The Management Of Paripluta Yonivyapad(Pelvic Inflammatory Disease)-An Open Labelled Randomized Comparative Clinico-Experimental Trial - MPPD

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025570
Enrollment
60
Registered
2020-06-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N738- Other specified female pelvic inflammatory diseases

Interventions

Intervention1: Dashamoola Taila group: Dashamoola Taila Yonipichu, Dose: 10ml, frequency: once at night in Pichu form till Aamutra Kaala, Duration: 10 days after stoppage of menses for two consecutiv

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda Gujarat Ayurved University Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Vedana in Shroni, Vankshana, Prushtha (Pain in pelvic, inguinal and lower back region, bilateral lower abdomen) 2.Shoona (Inflammation in genital tract), 3.Gramyadharme Ruja (Dyspareunia), 4.Bastikukshi Gurutva (Heaviness in region of bladder and lower abdomen) 5.Cervical motion tenderness, Uterine tenderness, Adnexal tenderness 6.Oral temperature greater than 101�°F (38.3�°C), 7.abnormal cervical mucopurulent discharge or cervical friability, abundant white blood cells on microscopic evaluation of vaginal fluid, 8. elevated Erythrocyte Sedimentation Rate, elevated C-reactive protein. 9.Transvaginal ultrasound showing thickened fluid-filled tubes with or without free pelvic fluid or tubo-ovarian complex and pelvic infection 10.Pre diagnosed Laparoscopic findings consistent with PID

Exclusion criteria

Exclusion criteria: 1.Pregnant women. 2.Women with Hb 3.Hypersensitivity to drug and inability to conform the protocol 4.Ovarian malignant tumor. 5.Patient with HIV, HbsAg, VDRL infection 6.Pelvic endometriosis 7.Patient with uncontrolled Hypertension, Tuberculosis, DM, any other severe systemic disease

Design outcomes

Primary

MeasureTime frame
Improvement in cardinal and associated clinical features related to Paripluta Yonivyapad (pelvic inflammatory disease)Timepoint: 60 days—

Secondary

MeasureTime frame
Improvement in all other investigatory parametersTimepoint: 60 days—

Countries

India

Contacts

Public ContactDr Shilpa B Donga

Institute for Post Graduate Teaching and Research in Ayurveda

drshilpadonga@yahoo.com9825646796

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026